Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercytex

www.Intercytex.com

Latest From Intercytex

STOCKWATCH: How to hide the meaning of clinical data

Investors like to be informed. So it is more than a little frustrating when public companies' clinical trial announcements omit important details; the way the trial was conducted, for instance, or the type of statistical analysis or the nature of the control with which a treatment was compared (scripintelligence.com, 16 July 2013).

Dermatology Cancer

Biologics: The Growth Engine In Advanced Wound Care

With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat. This article is reprinted from the June issue of Medtech Insight.
Medical Device

Biologics: The Growth Engine in Advanced Wound Care

With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat.
Medical Device

Biotech funding in a cold climate

Yesterday was the 92nd anniversary of the signing of the armistice that brought the hostilities of the First World War formally to an end. Coincidentally, it also marked the re-emergence of the UK-based regenerative medicine company Intercytex, which announced that its lead product, the cell therapy Vavelta, is to be evaluated by the US military to help treat injured soldiers.

Dermatology Wound Healing & Tissue Repair
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Intercytex
  • Senior Management
  • Nick Higgins, CEO
    Richard Moulson, CFO
    Paul Kemp, CSO
    Jan Benschop, VP, Commercial Dev.
  • Contact Info
  • Intercytex
    Phone: (44) 161 904 4500
    St. John's Innovation Centre
    Cowley Rd.
    Cambridge, CB4 0WS
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register